ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD25 Antibody-drug Conjugate PF-08046032

In Pfizer’s pipeline, CD25V directed antibody-drug conjugate. Its studies are mostly in Lymphoma, T-Cell, Peripheral, led by Pfizer.

Furthest: phase 1, since Feb 24, 20251 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer10 open or runningphase 1since Feb 24, 2025Feb 24, 2025none ahead
  • Named in Pfizer’s own pipeline as PF-08046032, phase 1, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 24, 2025First study: phase 1 study in Lymphoma, T-Cell, PeripheralFirst studyNCT06870487 · 6 enrolled · United States, Spain

TargetBeta

“CD25V directed antibody-drug conjugate”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a detuned-affinity monoclonal antibody directed against CD25 (interleukin-2 receptor subunit alpha; IL-2R alpha; IL-2Ra), conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. U…”NCIt, read by Claude

Other programs on IL2RA

ProgramCompanyFurthest phaseStudies
Interleukin-2rulechiron-corporationphase 411

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06870487Lymphoma, T-Cell, Peripheral · United States, Spain1TerminatedApr 23, 20266

How it is read

Names in the registry

  • “PF-08046032”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.